Melbourne Clinical Trials

Inhalation Study

The purpose of this study is to test a potential new treatment to lower the risk of rejection for people who have had a lung transplant. This study is evaluating how an already approved drug is absorbed when delivered via a different method.

3 nights
1 follow up call visits

The purpose of this study is to test a potential new treatment to lower the risk of rejection for people who have had a lung transplant. The drug that is being tested (Tacrolimus) is one of the most frequently used drugs globally for lung transplants and is currently administered via oral capsules or via an injection. In this study we want to see how it is absorbed by the body when it is administered via an inhaler (similar to an asthma pump). Inhalation of this medication was previously tested with 20 healthy volunteers in a safety study and was well tolerated.

The trial has been approved by an independent ethics committee and you will be reimbursed for your time.

Call us on 1800 243 733 to discuss your eligibility today!

Eligibility

Biological Sex Healthy males or females of non-childbearing potential (i.e. surgically sterile or post-menopausal)
Age 18 – 59 years old
BMI 18 – 32 kg/m²
Body Weight 50 – 120kg
Medication Not taking any
Medical History Nothing significant
Smoking History Non-smokers (no smoking within the past 3 months)